Advanced search

  • Endokrynologia Polska
  • Vol 71, No 1 (2020) Diagnosis and treatment of type 2 diabetes mellitus in patients with chronic kidney disease and eGFR < 60 mL/min — a position statement of the Polish Society of Nephrology Working Group on Metabolic and Endocrine Disorders in Kidney Diseases
Vol 71, No 1 (2020)
Guidelines / Expert consensus
Published online: 2020-02-24

open access

View PDF Download PDF file
Page views 4513
Article views/downloads 2333
Get Citation

Connect on Social Media

Connect on Social Media

Diagnosis and treatment of type 2 diabetes mellitus in patients with chronic kidney disease and eGFR < 60 mL/min — a position statement of the Polish Society of Nephrology Working Group on Metabolic and Endocrine Disorders in Kidney Diseases

Tomasz Stompór1, Marcin Adamczak2, Anna Masajtis-Zagajewska3, Oktawia Mazanowska4, Katarzyna Maziarska4, Agnieszka Witkowska2, Andrzej Więcek2
DOI: 10.5603/EP.a2019.0064
Pubmed: 32129464
Endokrynol Pol 2020;71(1):3-14.

Abstract

Diabetes mellitus is one the most frequent co-morbid conditions in patients with chronic kidney disease (CKD), frequently leading to chronic kidney failure. Progression of CKD accelerates several metabolic disorders, predominantly those related to abnormalities of carbohydrate metabolism. Patients with CKD are usually characterised by an insulin resistance additionally aggravated by several co-morbid conditions (for example chronic low-grade inflammation). Treatment with anti-diabetic medications in patients with CKD remains a challenge because, along with the disease progression, the dosing of several drugs needs to be adjusted to the reduced kidney function (especially those that are excreted intact with urine or as active metabolites). Progression of CKD also increases the risk of hypoglycaemia in patients treated with anti-diabetic drugs, and other adverse drug reactions may occur more frequently. Usefulness of the new generation drugs has not yet been verified in patients with advanced kidney disease (although some of them act through kidney-related mechanisms). The current position statement of the Polish Society of Nephrology Working Group provides practical recommendations for the diagnosis and treatment of type 2 diabetes mellitus in patients with CKD and reduced kidney function.

Keywords: type 2 diabetes mellituschronic kidney diseaseglucose metabolismoral anti-diabetic drugsincretin-based therapyinsulinadverse events

Article available in PDF format

View PDF Download PDF file

References

  1. Jaacks LM, Siegel KR, Gujral UP, et al. Type 2 diabetes: A 21st century epidemic. Best Pract Res Clin Endocrinol Metab. 2016; 30(3): 331–343.
    CrossRefPubMed
  2. Pyram R, Kansara A, Banerji MA, et al. Chronic kidney disease and diabetes. Maturitas. 2012; 71(2): 94–103.
    CrossRefPubMed
  3. Wu B, Bell K, Stanford A, et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012. BMJ Open Diabetes Res Care. 2016; 4(1): e000154.
    CrossRefPubMed
  4. Pugliese G, Solini A, Bonora E, et al. RIACE Study Group. Chronic kidney disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Nutr Metab Cardiovasc Dis. 2014; 24(8): 815–822.
    CrossRefPubMed
  5. Iglesias P, Díez JJ. Insulin therapy in renal disease. Diabetes Obes Metab. 2008; 10: 811–823.
    CrossRefPubMed
  6. Xu H, Carrero JJ. Insulin resistance in chronic kidney disease. Nephrology (Carlton). 2017; 22(Suppl 4): 31–34.
    CrossRefPubMed
  7. Leyking S, Fliser D. Insulin resistance in CKD. Clin J Am Soc Nephrol. 2014; 9(4): 638–640.
    CrossRefPubMed
  8. Sharif A, Hecking M, de Vries APJ, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014; 14(9): 1992–2000.
    CrossRefPubMed
  9. Fathallah N, Slim R, Larif S, et al. Drug-Induced Hyperglycaemia and Diabetes. Drug Saf. 2015; 38(12): 1153–1168.
    CrossRefPubMed
  10. Kovesdy CP, Sharma K, Kalantar-Zadeh K. Glycemic control in diabetic CKD patients: where do we stand? Am J Kidney Dis. 2008; 52(4): 766–777.
    CrossRefPubMed
  11. Guideline development group. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). Nephrol Dial Transplant. 2015; 30 Suppl 2: ii1–142.
    CrossRefPubMed
  12. Roche-Recinos A, Charlap E, Markell M. Management of glycemia in diabetic patients with stage IV and V chronic kidney disease. Curr Diab Rep. 2015; 15(5): 25.
    CrossRefPubMed
  13. American Diabetes Association . Updates to theStandards of Medical Care in Diabetes — 2018. Diabetes Care. 2018; 41(9): 2045–2047.
    CrossRefPubMed
  14. Gianchandani RY, Neupane S, Heung M. Hypoglycemia in Hospitalized Hemodialysis Patients With Diabetes: An Observational Study. J Diabetes Sci Technol. 2018; 12(1): 33–38.
    CrossRefPubMed
  15. Schernthaner G, Ritz E, Schernthaner GH. Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly? Nephrol Dial Transplant. 2010; 25(7): 2044–2047.
    CrossRefPubMed
  16. Arnouts P, Bolignano D, Nistor I, et al. Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. Nephrol Dial Transplant. 2014; 29(7): 1284–1300.
    CrossRefPubMed
  17. Di Lullo L, Mangano M, Ronco C, et al. The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents. Diabetes Metab Syndr. 2017; 11 Suppl 1: S295–S305.
    CrossRefPubMed
  18. Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014; 312(24): 2668–2675.
    CrossRefPubMed
  19. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011; 34(6): 1431–1437.
    CrossRefPubMed
  20. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014; 37(10): 2864–2883.
    CrossRefPubMed
  21. Penfornis A, Blicklé JF, Fiquet B, et al. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study. Vasc Health Risk Manag. 2014; 10: 341–352.
    CrossRefPubMed
  22. Lalau JD, Kajbaf F, Bennis Y, et al. Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4. Diabetes Care. 2018; 41(3): 547–553.
    CrossRefPubMed
  23. Kuo CC, Yeh HC, Chen B, et al. Prevalence of Metformin Use and the Associated Risk of Metabolic Acidosis in US Diabetic Adults With CKD: A National Cross-Sectional Study. Medicine (Baltimore). 2015; 94(51): e2175.
    CrossRefPubMed
  24. Schneider CA, Ferrannini E, Defronzo R, et al. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2008; 19(1): 182–187.
    CrossRefPubMed
  25. Davies M, Chatterjee S, Khunti K. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol. 2016; 8: 61–81.
    CrossRefPubMed
  26. Chaudhury A, Duvoor C, Reddy Dendi VS, et al. Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Front Endocrinol (Lausanne). 2017; 8: 6.
    CrossRefPubMed
  27. Roussel R, Lorraine J, Rodriguez A, et al. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease. Adv Ther. 2015; 32(11): 1029–1064.
    CrossRefPubMed
  28. Abe M, Okada K, Abe M, et al. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab. 2011; 12(1): 57–69.
    CrossRefPubMed
  29. Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet. 2015; 54(1): 1–21.
    CrossRefPubMed
  30. Muskiet MHA, Tonneijck L, Smits MM, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017; 13: 605.
    CrossRefPubMed
  31. Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375(4): 311–322.
    CrossRefPubMed
  32. Mann JFE, Ørsted DD, Buse JB, et al. LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377(9): 839–848.
    CrossRefPubMed
  33. Mentz RJ, Bethel MA, Merrill P, et al. EXSCEL Study Group, EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377(13): 1228–1239.
    CrossRefPubMed
  34. Gerstein HC, Colhoun HM, Dagenais GR, et al. REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394(10193): 121–130.
    CrossRefPubMed
  35. Gerstein HC, Colhoun HM, Dagenais GR, et al. REWIND Investigators. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019; 394(10193): 131–138.
    CrossRefPubMed
  36. Engel SS, Suryawanshi S, Stevens SR, et al. TECOS Study Group. Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. Diabetes Obes Metab. 2017; 19(11): 1587–1593.
    CrossRefPubMed
  37. Russo E, Penno G, Del Prato S. Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Diabetes Metab Syndr Obes. 2013; 6: 161–170.
    CrossRefPubMed
  38. Rosenstock J, Perkovic V, Johansen OE, et al. CARMELINA Investigators. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019; 321(1): 69–79.
    CrossRefPubMed
  39. Wanner C. EMPA-REG OUTCOME: The Nephrologist's Point of View. Am J Med. 2017; 130(6S): S63–S72.
    CrossRefPubMed
  40. Heerspink HJL, Perkins BA, Fitchett DH, et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016; 134(10): 752–772.
    CrossRefPubMed
  41. Perrone-Filardi P, Avogaro A, Bonora E, et al. Mechanisms linking empagliflozin to cardiovascular and renal protection. Int J Cardiol. 2017; 241: 450–456.
    CrossRefPubMed
  42. Schernthaner G, Mogensen CE, Schernthaner GH. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diab Vasc Dis Res. 2014; 11(5): 306–323.
    CrossRefPubMed
  43. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380: 347–357.
    CrossRefPubMed
  44. Fioretto P, Del Prato S, Buse JB, et al. DERIVE Study Investigators. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes Obes Metab. 2018; 20(11): 2532–2540.
    CrossRefPubMed
  45. Dekkers CCJ, Wheeler DC, Sjöström CD, et al. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease. Nephrol Dial Transplant. 2018; 33(11): 2005–2011.
    CrossRefPubMed
  46. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377(7): 644–657.
    CrossRefPubMed
  47. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117–2128.
    CrossRefPubMed
  48. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375: 323–334.
    CrossRefPubMed
  49. Perkovic V, Jardine MJ, Neal B, et al. CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019; 380(24): 2295–2306.
    CrossRefPubMed
  50. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation. 2019; 140(9): 739–750.
    CrossRefPubMed
  51. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018; 61(12): 2461–2498.
    CrossRefPubMed
  52. Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group . 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019 [Epub ahead of print].
    CrossRefPubMed
  53. Rajput R, Sinha B, Majumdar S, et al. Consensus statement on insulin therapy in chronic kidney disease. Diabetes Res Clin Pract. 2017; 127: 10–20.
    CrossRefPubMed
  54. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004; 17(5): 365–370.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice